pf-07104091
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 16, 2020 (NCT04553133)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07127770 | Phase 1 | Aug 28, 2025 | Pfizer |
| NCT05431153 | Phase 1 | Jun 10, 2022 | Pfizer |
| NCT05262400 | Phase 2 | Mar 14, 2022 | Pfizer |
| NCT04553133 | Phase 2 | Sep 16, 2020 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 2 | 2020 |
1 organizations
Page 1 / 1